Pan-Cancer NGS Panel
This 65-gene NGS panel is designed to profile solid tumor patients for actionable mutations in oncogenes and tumor suppressor genes in clinical studies and clinical trials.
Introducing OptiSeq™ Pan-Cancer NGS Panel
Opti-seq™ Pan-cancer 65-gene NGS panel is a targeted NGS panel containing 65 common oncogenes and tumor suppressor genes within 2900 amplicons. These hot mutations include important known mutations, some of which are actionable drug targets. The profiling of solid tumor patients with important mutations provides valuable information in drug therapy clinical studies or trials.
Samples tested: Liquid biopsy (blood/ccfDNA) and FFPE samples (tissue/DNA)
Low DNA input needed: 10ng for detection of somatic mutations (SNP); 100pg for germline mutations
Highly sensitive NGS test allows as low as 1% variant allele frequency (VAF) detection
Sample receipt to clinical report within 10 days. No deep sequencing is required
Comprehensive clinically significant variants, FDA-approved therapies and clinical trials
100% observed uniformity at ≥ 0.2X mean depth and 97% observed uniformity at ≥ 0.5X
Many targeted NGS panels target a particular type of cancer. However, when a clinical trial target multiple types of solid tumors, individual cancer NGS panels cannot cover the mutations important for various types of cancers. The Pan-cancer NGS panel contains mutations found in major types of solid tumors. A clinical study or trials that include drug testing on various solid tumors will benefit from this panel.
OptiSeq™ Pan-Cancer Gene Panel (65 Genes)